title: Psychiatric disorders in rapid-onset dystonia-parkinsonism.
abstract: OBJECTIVE
  Rapid-onset dystonia-parkinsonism (RDP) is caused by a variety of missense mutations in the ATP1A3 gene. Psychiatric comorbidity has been reported, although systematic examination of psychiatric disease in individuals with RDP is lacking. This study examines psychiatric morbidity for 23 patients with RDP in 10 families with family member control subjects and in 3 unrelated patients with RDP, totaling 56 individuals.
  
  
  METHODS
  Twenty-nine ATP1A3 mutation-positive individuals were examined; 26 exhibited motor symptoms (motor manifesting carrier [MMC]) and 3 did not (nonmotor manifesting carriers [NMC]). Twenty-seven ATP1A3 mutation-negative participants (noncarriers [NC]) were included. Rates of psychiatric illness for patients with RDP and related asymptomatic gene mutation carriers were compared with those for related nonmutation carriers. Outcome measures included the Unified Parkinson's Disease Rating Scale, Burke-Fahn-Marsden Dystonia Rating Scale, Instrumental Activities of Daily Living, Composite International Diagnostic Interview, Structured Clinical Interview for DSM-IV, Hamilton Depression Scale, Hamilton Anxiety Scale, and Yale-Brown Obsessive-Compulsive Scale.
  
  
  RESULTS
  NMC participants did not report any history of psychiatric disorder. Findings in MMC and NC groups included anxiety (MMC 48, NC 41%), mood (MMC 50%, NC 22%), psychotic (MMC 19%, NC 0%), and substance abuse/dependence (MMC 38%, NC 27%).
  
  
  CONCLUSIONS
  ATP1A3 mutations cause a wide spectrum of motor and nonmotor features. Psychotic symptoms tended to emerge before or concurrent with motor symptom onset, suggesting that this could be another expression of the ATP1A3 gene mutation.
authors.affiliation: Department of Neurology, Wake Forest School of Medicine, Wake Forest Baptist Health, Winston-Salem, NC, USA. abrashea@wakehealth.edu
authors.forename: Allison
authors.initials: A
authors.lastname: Brashear
authors.forename: Jared F
authors.initials: JF
authors.lastname: Cook
authors.forename: Deborah F
authors.initials: DF
authors.lastname: Hill
authors.forename: Alethea
authors.initials: A
authors.lastname: Amponsah
authors.forename: Beverly M
authors.initials: BM
authors.lastname: Snively
authors.forename: Laney
authors.initials: L
authors.lastname: Light
authors.forename: Niki
authors.initials: N
authors.lastname: Boggs
authors.forename: Cynthia K
authors.initials: CK
authors.lastname: Suerken
authors.forename: Mark
authors.initials: M
authors.lastname: Stacy
authors.forename: Laurie
authors.initials: L
authors.lastname: Ozelius
authors.forename: Kathleen J
authors.initials: KJ
authors.lastname: Sweadner
authors.forename: W Vaughn
authors.initials: WV
authors.lastname: McCall
mesh_terms: D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020821:Dystonic Disorders / Q000150:complications* / Q000235:genetics / Q000523:psychology; D005260:Female; D006579:Heterozygote; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications* / Q000175:diagnosis / Q000235:genetics; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D000254:Sodium-Potassium-Exchanging ATPase / Q000235:genetics
chemical_list: C488756:ATP1A3 protein, human; D000254:Sodium-Potassium-Exchanging ATPase